Skip to main content
. 2022 Jan 12;18(1):2013693. doi: 10.1080/21645515.2021.2013693

Figure 5.

Figure 5.

Impact of PCV13 and PHiD-CV on complex, complicated, recurrent and hospitalized otitis media (OM).

IS, Iceland; US, United States; y, years of age. *Mean age of cohorts over the study period was <3 years. **Includes children who received a primary course of at least two doses of PHiD-CV or PCV7. Horizontal lines show 95% confidence intervals when available. References: Marom42; Laursen43; Tawfik44; Wiese34; Leach46; Sigurdsson47.